Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

AIMS: To investigate the efficacy and tolerability of empagliflozin added to basal insulin‐treated type 2 diabetes. METHODS: Patients inadequately controlled [glycated haemoglobin (HbA1c) >7 to ≤10% (>53 to ≤86 mmol/mol)] on basal insulin (glargine, detemir, NPH) were randomized to empaglifloz...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U. C., Woerle, H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034797/
https://www.ncbi.nlm.nih.gov/pubmed/26040302
http://dx.doi.org/10.1111/dom.12503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034797/
https://www.ncbi.nlm.nih.gov/pubmed/26040302
http://dx.doi.org/10.1111/dom.12503

Ejemplares similares